<DOC>
	<DOCNO>NCT01831544</DOCNO>
	<brief_summary>This multi-center , prospective , non-randomized , single-arm trial investigate safety performance HeartWare® Miniaturized Ventricular Assist Device ( MVAD® ) system 24 month subject advance heart failure</brief_summary>
	<brief_title>A Clinical Trial Evaluate HeartWare MVAD® System ( MVAdvantage )</brief_title>
	<detailed_description>This multi-center , prospective , non-randomized , single-arm trial investigate safety performance Miniaturized Ventricular Assist Device ( MVAD® ) system 24 month subject advance heart failure . The primary endpoint survival 6 month present simple proportion ( subject alive MVAD® pump divide endpoint eligible subject ) . Secondary endpoint include incidence bleeding , incidence major infection ( per INTERMACS definition ) , time death , incidence device failure device malfunction , Health Status improvement , Functional status improvement . Safety measure include frequency rate adverse event , overall specific event , collect throughout VAD support .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Must ≥18 year age consent 2 . Subjects advance heart failure symptom ( Class IIIB IV ) meet one follow ) : 1. optimal medical management include dietary salt restriction diuretic , least 45 last 60 day fail respond ; 2. Class III Class IV heart failure least 14 day dependent intraaortic balloon pump ( IABP ) and/or inotropes . 3 . Left ventricular ejection fraction ≤25 % . 4 . Female subject childbearing potential must agree use adequate contraceptive precaution ( defined oral contraceptive , intrauterine device , surgical contraceptive combination condom spermicide ) duration study . 5 . The subject sign informed consent form . 1 . Body Mass Index ( BMI ) &gt; 47 . 2 . Body Surface Area ( BSA ) &lt; 1.0 m2 . 3 . Partial full mechanical circulatory support within thirty day implant . 4 . Existence ongoing mechanical circulatory support ( MCS ) intraaortic balloon pump ( IABP ) TandemHeart PTVA® . 5 . Prior cardiac transplant cardiomyoplasty . 6 . History confirm , untreated abdominal thoracic aortic aneurysm ( diameter &gt; 5 cm ) . 7 . Acute myocardial infarction within 14 day implant diagnosed ST T wave change electrocardiogram ( ECG ) , diagnostic biomarkers , ongoing pain hemodynamic abnormality . 8 . On ventilator support &gt; 72 hour within four day immediately prior implant . 9 . Pulmonary embolus within three week implant document computed tomography ( CT ) scan nuclear scan . 10 . Symptomatic cerebrovascular disease , stroke within 180 day implant &gt; 80 % stenosis carotid cranial vessel absence confirm collateral circulation 11 . Uncorrected moderate severe aortic insufficiency . 12 . Severe right ventricular failure define anticipated need extracorporeal membrane oxygenation ( ECMO ) time screen . 13 . Active , uncontrolled infection diagnose combination clinical symptom laboratory testing , include limited , continue positive culture , elevated temperature white blood cell ( WBC ) count , hypotension , tachycardia , generalize malaise despite appropriate antibiotic , antiviral antifungal treatment . 14 . Uncorrected thrombocytopenia generalize coagulopathy ( e.g. , platelet count &lt; 75,000 , International Normalized Ratio ( INR ) &gt; 2.0 Partial Thromboplastin Time ( PTT ) &gt; 2.5 time control absence anticoagulation therapy ) . 15 . Intolerance anticoagulant antiplatelet therapy peri postoperative therapy investigator may administer base upon subject 's health status . 16 . Serum creatinine &gt; 3.0 mg/dL within 72 hour implant require dialysis . 17 . Specific liver enzymes [ Aspartate Aminotransferase ( AST ) ( SGOT ) , Alanine Aminotransferase ( ALT ) ( SGPT ) ] &gt; 3 time upper limit normal within 72 hour implant . 18 . A total bilirubin &gt; 3 mg/dL within 72 hour implant , biopsy proven liver cirrhosis portal hypertension . 19 . Pulmonary vascular resistance ( PVR ) demonstrate unresponsive pharmacological manipulation . 20 . Subjects mechanical heart valve . 21 . Etiology heart failure due , associate , uncorrected thyroid disease , obstructive cardiomyopathy , pericardial disease , amyloidosis , active myocarditis restrictive cardiomyopathy . 22 . History severe COPD severe restrictive lung disease ( e.g . FEV1 &lt; 50 % predict value ) . 23 . Participation trial involve investigational drug device within 4 week prior screen last visit trial . 24 . Severe illness , heart disease , would limit survival &lt; 3 year . 25 . Peripheral vascular disease rest pain ischemic ulcer extremity . 26 . Pregnancy breast feed . 27 . Psychiatric disease , irreversible cognitive dysfunction psychosocial issue likely impair compliance CIP LVAD . 28 . Subject unwilling unable comply trial requirement . 29 . Technical obstacle , pose inordinately high surgical risk , judgment investigator . 30 . Employees investigator trial site , direct involvement trial trial direction investigator trial site , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>